Phase 2 HS win and $472M war chest position abdakibart for Phase 3, contingent on replicating that signal at registrational scale

Bull

A positive Phase 3 outcome would require abdakibart to demonstrate statistically significant HiSCR75 response rates meaningfully above placebo, consistent with the 42–43% absolute response seen in LOTUS, with a clean safety profile and durable benefit on secondary endpoints such as IHS4 and draining tunnel count. Such a result would support NDA submission and position abdakibart as a differentiated monthly-dosed biologic in a growing HS market, validating the full capital deployment thesis and likely triggering a substantial re-rating.

Bear

The most likely failure modes are a placebo response rate inflation at Phase 3 scale — a well-documented phenomenon in HS trials — that compresses the treatment delta below statistical significance, or heterogeneity in the broader Phase 3 population diluting the effect size seen in the more selected LOTUS cohort. A partial miss, such as hitting HiSCR50 but failing HiSCR75, or a safety signal requiring label restrictions, would materially impair the commercial profile and raise questions about whether the Phase 2 signal was reproducible.